BioSpace News Archive

Legion Healthcare Partners is pleased to announce the addition of James Welsh, MD to its Scientific Advisory Board. Dr. Welsh is an Associate Professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center.

Reducing false positive sepsis tests creates capacity for critical PCR lab equipment and increases bed availability

Health Vector and Primetime Medical Software announced an exclusive partnership that brings the leading strengths of each company to transform patient engagement through a new class of health management apps.

What’s New: Today, Intel announced the readiness of Pohoiki Springs, its latest and most powerful neuromorphic research system providing the computational capacity of 100 million neurons. The cloud-based system will be made available to members of the Intel Neuromorphic Research Community (INRC), extending their neuromorphic work to solve larger, more complex problems.

Rapid Antibody Test Generates Results in under 15 minutes from Blood Drop without Laboratory Equipment or Personnel

In light of the unprecedented demand and urgent need for products that can help limit the spread of COVID-19—including hand sanitizers, disinfectants and personal protective equipment (such as masks and gowns)—as well as swabs, Health Canada is facilitating access to products that may not fully meet current regulatory requirements, as an interim measure.

Medtronic plc announced that it will more than double its capacity to manufacture and supply ventilators, in response to the urgent needs of patients and healthcare system across the globe as we confront the COVID-19 virus.

The global biological therapeutics market mainly comprises of derivatives extracted from whole blood and other blood components, organs and tissue transplants, stem cell therapy, human breast milk, fecal microbiota, human reproductive cells, and antibodies.

The future of joint pain injection market is expected to be bright. With breakthrough developments in healthcare every now and again for improving patient care, joint pain complaints, a small concern it may be, has received due attention in clinical trials for numerous disease therapeutics.

According to the report, the global neurological disorder drugs market was valued at ~US$ 70 Bn in 2018 and is projected to expand at a CAGR of ~5% from 2019 to 2027.